Jason Oeh
Genesys (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Advanced Breast Cancer Therapies, Peptidase Inhibition and Analysis
Most-Cited Works
- → Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway(2012)469 cited
- → Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models(2016)308 cited
- → Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models(2013)293 cited
- → Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility(2019)218 cited
- → Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors(2012)184 cited
- → GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer(2021)132 cited
- → Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase(2014)83 cited
- → Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618(2013)79 cited
- → Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models(2013)58 cited
- → Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)(2013)41 cited